Lp(a), or lipoprotein(a), stayed off the radar of everyday medicine for decades. Unlike LDL cholesterol, it cannot be lowered by diet, exercise or statins: it is set genetically at birth. Two recent developments now change the picture, a screening test recommended for everyone, and a new generation of treatments in advanced clinical trials. For anyone thinking about their health over several decades, this is information worth having early.
In brief – Lp(a) is a cholesterol-carrying particle closely related to LDL, whose blood level is determined by genetics rather than lifestyle and stays stable for life, so one test at any age is enough to know your number. About 20% of people worldwide, roughly 1.4 billion, carry an elevated level that raises the risk of heart attack and stroke through both plaque buildup and increased clotting. A single case in a family can point to first-degree relatives who carry the same genetic risk. No diet, supplement or lifestyle habit lowers it meaningfully, but four to five targeted drugs, including pelacarsen and olpasiran, are now in late-stage trials with reductions of up to 94% in blood levels, and outcome results are expected within a few years.
What Is Lp(a)?
Lp(a) is a particle closely related to LDL, carrying an extra protein called apolipoprotein(a) attached to apoB-100. This structure gives it two harmful effects at once, it promotes plaque buildup in artery walls the way ordinary LDL does, and it has clot-promoting properties that raise the risk of dangerous blockages. According to MedlinePlus, cholesterol particles like Lp(a) circulate in the blood and their levels are shaped heavily by inherited genetic factors, more than 90% in the case of Lp(a) specifically.
Around 20% of the general population, an estimated 1.4 billion people worldwide, carries an elevated level. Once measured, that level stays the same for life. Unlike LDL, there is no seasonal or dietary window to monitor. A single blood draw, done once, is enough.
Why This Risk Factor Went Unnoticed for So Long
Three reasons explain this historical blind spot.
- It does not show up on a standard lipid panel. Measuring it requires a specific test, separate from routine LDL and HDL cholesterol screening.
- Until recently, no targeted treatment existed. Statins, ezetimibe and most cholesterol-lowering drugs have almost no effect on it, which limited the perceived clinical value of testing for it.
- Insurance coverage was long uncertain in the United States, with some payers labeling the test “experimental” despite its low cost, 24 to 50 dollars.
That last point has shifted. A Class I recommendation for universal screening was issued in 2026, and the National Lipid Association has recommended since 2024 that every adult learn their level at least once in their lifetime.
The Longevity Angle: Why Knowing Early Changes Everything
This is where the longevity dimension matters most. Because Lp(a) is fixed genetically and stable for life, knowing your level at 30 or 40, well before any symptom appears, lets you adjust a prevention strategy over decades rather than discovering the problem after a first cardiovascular event.
- An elevated level lowers the treatment threshold for every other risk factor. A cardiologist aware of a patient’s high Lp(a) will manage blood pressure, LDL and apoB more aggressively, even when those markers otherwise look “acceptable.”
- Cascade family screening is unusually cost-effective. If your level is high, first-degree relatives (parents, siblings, children) have roughly a 50% chance of carrying the same genetic predisposition. One test can reveal the risk for an entire family, sometimes decades before a cardiac event occurs.
- The prevention window is long. An elevated level found at age 35 leaves potentially 20 to 30 years to optimize every modifiable lever (apoB, blood pressure, lifestyle) before plaque buildup becomes clinically significant.
Those modifiable levers are exactly what make the difference over time. Keeping up regular physical activity and paying attention to diet quality, including omega-3 sources that support the cardiovascular system, remain the foundation of effective prevention.
What Doesn’t Work, and What to Avoid
One point deserves emphasis, Lp(a) does not respond to the approaches that usually work on other cardiovascular markers. Fasting, sauna use and most dietary supplements do not lower it by any clinically meaningful amount. High-dose niacin (vitamin B3) can modestly reduce the number, but large clinical trials found no benefit on actual cardiovascular events, and its use comes with real side effects. Any commercial product promising to “lower your Lp(a)” through non-drug means deserves skepticism. Acting on other drivers of artery health, on the other hand, remains fully worthwhile.
New Treatments in Development
This is the most significant shift, after decades without a targeted therapy, four to five drugs are now in advanced clinical trials, with striking reductions in blood levels.
| Drug | Company | Mechanism | Observed reduction |
|---|---|---|---|
| Pelacarsen | Novartis/Ionis | Antisense oligonucleotide (blocks liver production) | Up to 80% |
| Olpasiran | Amgen | Small interfering RNA (siRNA) | Marked reduction, OCEAN(a)-Outcomes trial ongoing |
| Lepodisiran | Eli Lilly | siRNA, twice-yearly injection | Up to 94% |
| Muvalaplin | Eli Lilly | Oral drug, blocks assembly of the Lp(a) particle | 47 to 85%, depending on dose |
These figures describe reductions in blood Lp(a) levels, a biological result confirmed by early-phase trials published in JAMA, not yet clinical proof of fewer heart attacks and strokes. That question is precisely what the large cardiovascular outcome trials now underway aim to answer.
- Lp(a)HORIZON (pelacarsen): results expected soon, the first trial of this scale able to answer the key question.
- OCEAN(a)-Outcomes (olpasiran): more than 7,000 patients with established cardiovascular disease and an elevated level.
- ACCLAIM-Lp(a) (lepodisiran): about 17,000 participants expected, results estimated around 2029.
- MOVE-Lp(a) (muvalaplin, oral): phase 3 trial currently recruiting.
The open question is no longer whether Lp(a) can be lowered, that part works, but whether lowering it actually translates into fewer heart attacks and strokes. Mendelian randomization analyses published in JAMA Cardiology suggest that a large, sustained reduction is needed to produce a measurable clinical benefit. A definitive answer, one that would reshape preventive cardiology broadly, is expected within the next few years.
Key Takeaways
- Lp(a) is a major, independent cardiovascular risk factor, genetic and stable for life, distinct from LDL.
- A single, inexpensive test is now recommended for every adult.
- An elevated level cannot be corrected through lifestyle, but it justifies stricter management of every other modifiable risk factor.
- Cascade family screening multiplies the value of a single test.
- A new generation of targeted treatments, currently in phase 3 trials, could transform cardiovascular prevention by the end of the decade, without replacing the fundamentals of blood pressure, apoB and physical activity, at least for now.
From a longevity standpoint, this marker illustrates a broader principle, the most cost-effective prevention acts decades before symptoms appear, based on information you only get by actively seeking it out.
Frequently Asked Questions
How do you get your Lp(a) tested?
Simply ask for it during a routine blood draw, this is a specific test, separate from a standard lipid panel, so it must be ordered explicitly. One test in a lifetime is enough, since the level stays stable.
Is a high Lp(a) level a foregone conclusion?
No. The level itself does not change with lifestyle, but knowing it is elevated lets you act earlier and more firmly on every other modifiable risk factor (blood pressure, apoB, physical activity), which lowers overall risk.
Is Lp(a) the same thing as LDL cholesterol?
No. Lp(a) resembles LDL but carries an extra protein, apolipoprotein(a), which gives it its own clot-promoting effect. It is an independent risk factor that a standard LDL test does not capture.
Is there a drug available today to lower Lp(a)?
No targeted treatment is approved yet, but several drugs (pelacarsen, olpasiran, lepodisiran, muvalaplin) are in phase 3 trials and sharply reduce blood levels. Their benefit on heart attacks and strokes is still being evaluated.
Medical disclaimer. The information on this page is provided for informational purposes only and does not constitute medical advice. It does not replace a consultation. Ask a healthcare professional before changing your diet, taking dietary supplements or starting a new practice, especially if you have a medical condition, are pregnant or are under treatment. Dietary supplements do not replace a balanced diet or medical follow-up.
